<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00112229</url>
  </required_header>
  <id_info>
    <org_study_id>LUD 2000-018</org_study_id>
    <nct_id>NCT00112229</nct_id>
  </id_info>
  <brief_title>Immunotherapy of HLA-A2 Positive Stage III/IV Melanoma Patients</brief_title>
  <official_title>Immunotherapy of HLA-A2 Positive Stage III/IV Melanoma Patients With CpG7909, Tumor Antigenic Peptides and Montanide</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Vaudois</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ludwig Institute for Cancer Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire Vaudois</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether vaccination with tumor antigenic peptides
      and both CpG and Montanide adjuvants can induce an immune response in melanoma patients and
      to assess the safety of this vaccination.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Immune therapy with tumor antigenic peptides is generally quite well tolerated. However,
      immune activation is often only weak or even undetectable, and clinical responses (supposedly
      corresponding to protective immunity) are unfortunately infrequent. Further progress is
      required to improve the vaccines, with the goal to increase the strength of immune
      activation.

      The tumor antigenic peptides Melan-A/Mart-1 (EAA and ELA) and Tyrosinase (YMD) are combined
      with two drugs in this study, both of which are known to enhance immune responses: first, CpG
      7909 oligodeoxynucleotides, and second, Montanide ISA-51.

        -  Group 1: vaccination with Melan-A analog peptide + CpG and Montanide adjuvants;

        -  Group 2: vaccination with Melan-A natural peptide + CpG and Montanide adjuvants;

        -  Group 3 : vaccination with Melan-A natural and Tyrosinase peptides + CpG and Montanide
           adjuvants;

        -  Group 4 : vaccination with Melan-A analog and Tyrosinase peptides + CpG and Montanide
           adjuvants.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2003</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Melan-A and Tyrosinase specific CD8+ T-cell reactivity will be measured by Tetramers and Elispot assays</measure>
    <time_frame>Change from baseline in CD8 T-cells reactivity at day 375</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety of vaccination will be assessed according to National Cancer Institute Common Toxicity Criteria (NCI CTC) scale</measure>
    <time_frame>Change from baseline to day 375</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>In patients with measurable disease, tumor response will be assessed radiologically</measure>
    <time_frame>Change from baseline in tumor response at day 375</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Melan-A analog peptide + CpG + Montanide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Melan-A natural peptide + CpG + Montanide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Melan-A natural peptide + Tyrosinase YMD peptide + CpG + Montanide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Melan-A analog peptide + Tyrosinase YMD peptide + CpG + Montanide</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>group 1</intervention_name>
    <description>Melan-A analog peptide + CpG + Montanide</description>
    <arm_group_label>group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>group 2</intervention_name>
    <description>Melan-A natural peptide + CpG + Montanide</description>
    <arm_group_label>group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>group 3</intervention_name>
    <description>Melan-A natural peptide + Tyrosinase YMD peptide + CpG + Montanide</description>
    <arm_group_label>group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>group 4</intervention_name>
    <description>Melan-A analog peptide + Tyrosinase YMD peptide + CpG + Montanide</description>
    <arm_group_label>group 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed stage III or stage IV melanoma

          -  Tumor expression of Melan-A +/- Tyrosinase

          -  Human leukocyte antigen-A2 (HLA-A2) positive

        Exclusion Criteria:

          -  Clinically significant heart disease

          -  Serious illnesses, eg, serious infections requiring antibiotics, bleeding disorders or
             uncontrolled peptic ulcer, or seizure or central nervous system disorders

          -  History of immunodeficiency disease or autoimmune disease

          -  Coagulation or bleeding disorders
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivier Michielin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ludwig Institute for Cancer Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ludwig Institute for Cancer Research + Multidisciplinary Oncology Center at the Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <state>Vaud</state>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <results_reference>
    <citation>Speiser DE, Liénard D, Rufer N, Rubio-Godoy V, Rimoldi D, Lejeune F, Krieg AM, Cerottini JC, Romero P. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest. 2005 Mar;115(3):739-46.</citation>
    <PMID>15696196</PMID>
  </results_reference>
  <results_reference>
    <citation>Baumgaertner P, Jandus C, Rivals JP, Derré L, Lövgren T, Baitsch L, Guillaume P, Luescher IF, Berthod G, Matter M, Rufer N, Michielin O, Speiser DE. Vaccination-induced functional competence of circulating human tumor-specific CD8 T-cells. Int J Cancer. 2012 Jun 1;130(11):2607-17. doi: 10.1002/ijc.26297. Epub 2011 Aug 24.</citation>
    <PMID>21796616</PMID>
  </results_reference>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 31, 2005</study_first_submitted>
  <study_first_submitted_qc>May 31, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 1, 2005</study_first_posted>
  <last_update_submitted>April 19, 2013</last_update_submitted>
  <last_update_submitted_qc>April 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 22, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre Hospitalier Universitaire Vaudois</investigator_affiliation>
    <investigator_full_name>Prof Olivier Michielin, M.D., Ph.D.</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Immunotherapy</keyword>
  <keyword>Vaccination</keyword>
  <keyword>Melanoma</keyword>
  <keyword>Melan-A/Mart-1 peptide</keyword>
  <keyword>Tyrosinase peptide</keyword>
  <keyword>CpG</keyword>
  <keyword>Montanide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>January 19, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

